Glenmark Pharmaceuticals Limited Financial Overview
Glenmark Pharmaceuticals Limited's market cap is currently ₹561.79B. The company's EPS TTM is ₹21.62; its P/E ratio is 55.63; and it has a dividend yield of 0.25%. Glenmark Pharmaceuticals Limited is scheduled to report earnings on November 14, 2025, and the estimated EPS forecast is ₹―. See an overview of income statement, balance sheet, and cash flow financials.
